Real-world study of Koselugo (selumetinib) in South Korea
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This study looks at how patients with certain conditions are doing while taking Koselugo (selumetinib) in real life. It's a way to gather information about the treatment's effectiveness and safety outside of a controlled clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already taken or be taking Koselugo (selumetinib) as prescribed by your doctor.
- Your treatment must be happening in South Korea under the approved guidelines.
- You (or your legal guardian) must sign a consent form allowing your medical information to be used for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
This trial tests a capsule medication (smetinib) for people with type 1 neurofibromatosis (NF1) who have tumors that can be surgically removed but have not spread to vital areas like the brain or spine. The goal is to see if the drug can help shrink or control these tumors.
This trial tests a new pill (smeitinib) to shrink tumors caused by neurofibromatosis type 1 (NF1). It is for adults with NF1 who have tumors that cannot be removed by surgery, including those that press on the brain or spine.
This study looks at real-world safety data for patients in South Korea who are taking Capivasertib as prescribed by their doctor according to the approved label. It helps ensure the drug continues to be safe and effective for people who need it.
This study is tracking the safety and effectiveness of a drug called Poteligeo (mogamulizumab) for adults with mycosis fungoides or Sézary syndrome who have already tried at least one body-wide treatment. It is a post-market surveillance study, meaning the drug is already approved, and doctors are gathering real-world information about how well it works and any side effects.
Hear when a new Neurofibromatosis 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.